Anticancer Section / Original Paper

Annibali O.a· Tomarchio V.a· Gregorj C.a· Di Cerbo M.b· Armiento D.a· Antonelli L.a· Vincenzi B.c· Nobile C.b· Vacca M.b· Tirindelli M.C.b· Avvisati G.a

Author affiliations

aHematology and Stem Cell Transplantation, Fondazione Policlinico Campus Bio-Medico, Rome, Italy
bTransfusion Medicine and Cell Therapy, Fondazione Policlinico Campus Bio-Medico, Rome, Italy
cMedical Oncology, Department of Medicine, Università Campus Bio-Medico di Roma, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Received: October 26, 2022
Accepted: January 02, 2023
Published online: March 09, 2023

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Abstract

Introduction: Neoangiogenesis has a crucial role in multiple myeloma (MM), and circulating endothelial cells (CECs) contribute to neovascularization by inducing tumor progression and metastasis and by repairing damage to bone marrow vasculature after stem cell transplantation (HSC). We recently proved in a national multicenter study the possibility to reach a high-level standardization in CEC count and analysis based on a polychromatic flow cytometry Lyotube (BD). Our study aimed at assessing the kinetics of CECs in patients with MM undergoing autologous hematopoietic stem cell transplantation (Au-HSCT). Methods: Blood samples for analysis were collected at different time points before (T0, T1) and after (T2, T3, T4) Au-HSCT. For each sample, 20 × 106 leukocytes were processed as already described (Lanuti 2016 e 2018) through a multistep procedure. CECs were eventually identified as 7-ADDneg/Syto16pos/CD45neg/CD34pos/CD146pos. Results: Twenty-six MM patients were enrolled in the study. Overall, we observed a constant increase of CECs values from T0 to T3 (day of neutrophil engraftment) followed by decrease at T4 (100 days after transplantation). Using the median value of CECs at T3, we could define a cut-off concentration of 618/mL, with patients with more infective complications having CECs above that value (9/13 vs. 2/13; p = 0.005). Conclusion: CECs value may be a function of endothelial damage caused by conditioning regimen, as suggested by the increase of their level during the engraftment period. A more severe endothelial damage is reflected by the increase of infective complications in patients with higher CECs value at T3.

© 2023 S. Karger AG, Basel

References Ruggeri A, Paviglianiti A, Volt F, Kenzey C, Rafii H, Rocha V, et al. Endothelial and circulating progenitor cells in hematological diseases and allogeneic hematopoietic stem cell transplantation. Curr Med Chem. 2018;25(35):4535–44. De la Puente P, Muz B, Azab F, Azab AK. Cell trafficking of endothelial progenitor cells in tumor progression. Clin Cancer Res. 2013;19(13):3360–8. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105(8):3286–94. Lanuti P, Rotta G, Almici C, Avvisati G, Budillon A, Doretto P, et al. Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR 2 and CD 133, are not detectable in healthy peripheral and cord blood. Cytometry A. 2016;89(3):259–70. Lanuti P, Simeone P, Rotta G, Almici C, Avvisati G, Azzaro R, et al. A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. Sci Rep. 2018;8(1):5823–10. Almici C, Neva A, Skert C, Bruno B, Verardi R, Di Palma A, et al. Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System. Sci Rep. 2019;9(1):87–12. Kideryová L, Pytlík R, Benešová K, Veselá R, Karban J, Rychtrmocová H, et al. Endothelial cells (EC) and Endothelial Precursor Cells (EPC) kinetics in hematological patients undergoing chemotherapy or Autologous Stem Cell Transplantation (ASCT). Hematol Oncol. 2010;28(4):192–201. Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Martine C, et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant. 2010; 16(7):985–93. Mengarelli A, Annibali O, Pimpinelli F, Riva E, Gumenyuk S, Renzi D, et al. Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. J Infect. 2016;72(2):265–8. Woywodt A, Scheer J, Hambach L, Buchholz S, Ganser A, Haller H, et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood. 2004;103(9):3603–5. Almici C, Skert C, Bruno B, Bianchetti A, Verardi R, Di Palma A, et al. Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(12):1637–42. Bhaskar A, Gupta R, Kumar L, Sharma A, Sharma MC, Kalaivani M, et al. Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leuk Lymphoma. 2012;53(4):635–40. Wang L, Du F, Zhang HM, Zhang WJ, Wang HX. Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone. Braz J Med Biol Res. 2015;48(8):736–42. Qiao J, Ding L, Fu J, Yao H, Li X, Chen C, et al. Endothelial progenitor cells improve the quality of transplanted hematopoietic stem cells and maintain longer term effects in mice. Ann Hematol. 2017;96(1):107–14. Article / Publication Details

Received: October 26, 2022
Accepted: January 02, 2023
Published online: March 09, 2023

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.